Hi ,The significant change to short term earnings is due to the deferral of milestone payments from Grunenthal attached to the commercialisation deal for MPC-06-ID for the treatment of chronic lower back pain. This adjustment reduces FY21 revenues by $57m. The company is yet to engage with the FDA on the design of the phase 3 confirmatory study and we now expect recruitment of a phase 3 to begin not before 4Q CY22.
Aloha.
MSB Trading 2021 - paradigm shift, page-5391
-
- There are more pages in this discussion • 4,820 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 94461 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 61151 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |